Hyperlipidemia is a common adverse effect of sirolimus (SRL). We previously showed significant associations of ABCB1 3435C>T and IL-10 -1082G>A with log-transformed SRL dose-adjusted, weighted-normalized trough. We further examined to see whether these polymorphisms were also associated with SRL-induced dyslipidemia.
Genotyping was performed for ABCB1 1236C>T, 2677 G>T/A, and 3435C>T, CYP3A4 -392A>G, CYP3A5 6986A>G and 14690G>A, IL-10 -1082G>A, TNF - 308G>A, and ApoEε2,ε3, and ε4 alleles. The longitudinal changes of total cholesterol (TC), low-density lipoprotein (LDL)-C, and triglyceride (TG) levels after SRL treatment prior to statin therapy were analyzed by a linear mixed-effects model, with adjustments for selected covariates for each lipid.
Under the dominant genetic model, ABCB1 3435C>T was associated with TC (p=0.0001) and LDL-C (p<0.0001) values after SRL administration. Mean TC and LDL-C levels were 26.9 and 24.9 mg/dL higher, respectively, in ABCB1 3435T carriers than 3435CC homozygotes at an average SRL trough concentration of 4 ng/mL without concomitant medication. ABCB1 1236C>T under the recessive model and IL-10 -1082G>A under the dominant model were associated with log-transformed TG values (p=0.0051 and 0.0436, respectively). Mean TG value was 25.1% higher in ABCB1 1236TT homozygotes compared to ABCB1 1236C carriers and was 12.4% higher in IL-10-1082AA homozygotes than -1082G carriers.
ABCB1 polymorphisms were found to be associated with lipid responses to SRL treatment, confirming the role of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics. Further studies are necessary to define the role of ABCB1 and IL-10 polymorphisms on SRL-induced dyslipidemia in renal transplantation.